INCYTE CORPORATION Cost of Revenue
INCYTE CORPORATION (INCY) reported Cost of Revenue of $104.52 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-04-28
- INCYTE CORPORATION cost of revenue for the quarter ending 2026-03-31 was $104.52M, a 42.81% increase year-over-year.
- INCYTE CORPORATION cost of revenue for the quarter ending 2025-12-31 was $121.17M, a 36.94% increase year-over-year.
- INCYTE CORPORATION cost of revenue for the quarter ending 2025-09-30 was $99.00M, a 15.13% increase year-over-year.
- INCYTE CORPORATION cost of revenue for the quarter ending 2025-06-30 was $78.77M, a 2.78% increase year-over-year.
- INCYTE CORPORATION cost of revenue for fiscal 2025 was $372.13M, a 19.25% increase from fiscal 2024.
- INCYTE CORPORATION cost of revenue for fiscal 2024 was $312.07M, a 22.38% increase from fiscal 2023.
- INCYTE CORPORATION cost of revenue for fiscal 2023 was $254.99M, a 23.19% increase from fiscal 2022.
- INCYTE CORPORATION cost of revenue for fiscal 2022 was $207.00M, a 37.09% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-03-31 | $104.52M 10-Q · filed 2026-04-28 | $225.70M derived: sum of 2 quarters · filed 2026-04-28 | $324.70M derived: sum of 3 quarters · filed 2026-04-28 | $403.46M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $121.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $220.18M derived: sum of 2 quarters · filed 2026-02-10 | $298.94M derived: sum of 3 quarters · filed 2026-02-10 | $372.13M 10-K · filed 2026-02-10 |
| 2025-09-30 | $99.00M 10-Q · filed 2025-10-28 | $177.77M derived: sum of 2 quarters · filed 2025-10-28 | $250.96M 10-Q · filed 2025-10-28 | $339.44M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-06-30 | $78.77M 10-Q · filed 2025-07-29 | $151.95M 10-Q · filed 2025-07-29 | $240.44M derived: sum of 3 quarters · filed 2026-04-28 | $326.43M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-03-31 | $73.19M 10-Q · filed 2026-04-28 | $161.67M derived: sum of 2 quarters · filed 2026-04-28 | $247.67M derived: sum of 3 quarters · filed 2026-04-28 | $324.30M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $88.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $174.48M derived: sum of 2 quarters · filed 2026-02-10 | $251.11M derived: sum of 3 quarters · filed 2026-02-10 | $312.07M 10-K · filed 2026-02-10 |
| 2024-09-30 | $85.99M 10-Q · filed 2025-10-28 | $162.63M derived: sum of 2 quarters · filed 2025-10-28 | $223.58M 10-Q · filed 2025-10-28 | $293.33M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $76.63M 10-Q · filed 2025-07-29 | $137.59M 10-Q · filed 2025-07-29 | $207.34M derived: sum of 3 quarters · filed 2026-02-10 | $267.43M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $60.96M 10-Q · filed 2025-04-29 | $130.71M derived: sum of 2 quarters · filed 2026-02-10 | $190.80M derived: sum of 3 quarters · filed 2026-02-10 | $259.12M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $69.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $129.84M derived: sum of 2 quarters · filed 2026-02-10 | $198.17M derived: sum of 3 quarters · filed 2026-02-10 | $254.99M 10-K · filed 2026-02-10 |
| 2023-09-30 | $60.09M 10-Q · filed 2024-10-29 | $128.42M derived: sum of 2 quarters · filed 2024-10-29 | $185.24M 10-Q · filed 2024-10-29 | $244.40M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-06-30 | $68.33M 10-Q · filed 2024-07-30 | $125.15M 10-Q · filed 2024-07-30 | $184.31M derived: sum of 3 quarters · filed 2025-02-10 | $238.90M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-03-31 | $56.82M 10-Q · filed 2024-04-30 | $115.98M derived: sum of 2 quarters · filed 2025-02-10 | $170.57M derived: sum of 3 quarters · filed 2025-02-10 | $221.21M derived: sum of 4 quarters · filed 2025-02-10 |
| 2022-12-31 | $59.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $113.75M derived: sum of 2 quarters · filed 2025-02-10 | $164.38M derived: sum of 3 quarters · filed 2025-02-10 | $207.00M 10-K · filed 2025-02-10 |
| 2022-09-30 | $54.58M 10-Q · filed 2023-10-31 | $105.22M derived: sum of 2 quarters · filed 2023-10-31 | $147.83M 10-Q · filed 2023-10-31 | $191.71M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $50.64M 10-Q · filed 2023-08-01 | $93.25M 10-Q · filed 2023-08-01 | $137.12M derived: sum of 3 quarters · filed 2024-02-13 | $176.99M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $42.61M 10-Q · filed 2023-05-02 | $86.49M derived: sum of 2 quarters · filed 2024-02-13 | $126.36M derived: sum of 3 quarters · filed 2024-02-13 | $164.38M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $43.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $83.74M derived: sum of 2 quarters · filed 2024-02-13 | $121.77M derived: sum of 3 quarters · filed 2024-02-13 | $150.99M 10-K · filed 2024-02-13 |
| 2021-09-30 | $39.87M 10-Q · filed 2022-11-01 | $77.90M derived: sum of 2 quarters · filed 2022-11-01 | $107.12M 10-Q · filed 2022-11-01 | $143.44M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-06-30 | $38.03M 10-Q · filed 2022-08-02 | $67.25M 10-Q · filed 2022-08-02 | $103.57M derived: sum of 3 quarters · filed 2023-02-07 | $137.89M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-03-31 | $29.22M 10-Q · filed 2022-05-03 | $65.54M derived: sum of 2 quarters · filed 2023-02-07 | $99.86M derived: sum of 3 quarters · filed 2023-02-07 | $133.23M derived: sum of 4 quarters · filed 2023-02-07 |
| 2020-12-31 | $36.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $70.64M derived: sum of 2 quarters · filed 2023-02-07 | $104.01M derived: sum of 3 quarters · filed 2023-02-07 | $131.33M 10-K · filed 2023-02-07 |
| 2020-09-30 | $34.32M 10-Q · filed 2021-11-02 | $67.69M derived: sum of 2 quarters · filed 2021-11-02 | $95.00M 10-Q · filed 2021-11-02 | $127.22M derived: sum of 4 quarters · filed 2022-02-08 |
| 2020-06-30 | $33.36M 10-Q · filed 2021-08-03 | $60.68M 10-Q · filed 2021-08-03 | $92.90M derived: sum of 3 quarters · filed 2022-02-08 | $122.94M derived: sum of 4 quarters · filed 2022-02-08 |
| 2020-03-31 | $27.32M 10-Q · filed 2021-05-04 | $59.53M derived: sum of 2 quarters · filed 2022-02-08 | $89.57M derived: sum of 3 quarters · filed 2022-02-08 | $118.98M derived: sum of 4 quarters · filed 2022-02-08 |
| 2019-12-31 | $32.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-08 | $62.26M derived: sum of 2 quarters · filed 2022-02-08 | $91.66M derived: sum of 3 quarters · filed 2022-02-08 | $114.25M 10-K · filed 2022-02-08 |
| 2019-09-30 | $30.04M 10-Q · filed 2020-11-05 | $59.45M derived: sum of 2 quarters · filed 2020-11-05 | $82.03M 10-Q · filed 2020-11-05 | $108.40M derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-06-30 | $29.41M 10-Q · filed 2020-08-04 | $51.99M 10-Q · filed 2020-08-04 | $78.36M derived: sum of 3 quarters · filed 2021-02-09 | $103.16M derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-03-31 | $22.59M 10-Q · filed 2020-05-05 | $48.95M derived: sum of 2 quarters · filed 2021-02-09 | $73.75M derived: sum of 3 quarters · filed 2021-02-09 | $98.61M derived: sum of 4 quarters · filed 2021-02-09 |
| 2018-12-31 | $26.37M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $51.16M derived: sum of 2 quarters · filed 2021-02-09 | $76.02M derived: sum of 3 quarters · filed 2021-02-09 | $94.12M 10-K · filed 2021-02-09 |
| 2018-09-30 | $24.80M 10-Q · filed 2019-10-29 | $49.65M derived: sum of 2 quarters · filed 2019-10-29 | $67.76M 10-Q · filed 2019-10-29 | $90.12M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $24.86M 10-Q · filed 2019-07-30 | $42.96M 10-Q · filed 2019-07-30 | $65.32M derived: sum of 3 quarters · filed 2020-02-13 | $87.36M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $18.11M 10-Q · filed 2019-04-30 | $40.47M derived: sum of 2 quarters · filed 2020-02-13 | $62.50M derived: sum of 3 quarters · filed 2020-02-13 | $82.76M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $22.36M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $44.40M derived: sum of 2 quarters · filed 2020-02-13 | $64.66M derived: sum of 3 quarters · filed 2020-02-13 | $79.48M 10-K · filed 2020-02-13 |
| 2017-09-30 | $22.04M 10-Q · filed 2018-10-30 | $42.30M derived: sum of 2 quarters · filed 2018-10-30 | $57.12M 10-Q · filed 2018-10-30 | |
| 2017-06-30 | $20.26M 10-Q · filed 2018-07-31 | $35.08M 10-Q · filed 2018-07-31 | ||
| 2017-03-31 | $14.82M 10-Q · filed 2018-05-01 | |||
| 2016-12-31 | $58.19M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |